Navigation Links
Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--May 23, 2007 - Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that survival and sub-population data from the Phase 2b clinical trial in metastatic melanoma of the Company's lead oncology drug candidate, STA-4783, will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois on Tuesday, June 5, 2007. In this double-blind, randomized, multi-center trial, patients treated with STA-4783 in combination with paclitaxel were compared with patients treated with paclitaxel alone. All patients had stage IV metastatic melanoma.

STA-4783 is a novel, injectable, small molecule investigational drug candidate that induces a potent oxidative stress response in cancer cells, driving programmed cell death and enhancing the activity of anti-cancer agents that act through the mitochondrial apoptosis pathway, including paclitaxel. In September 2006, Synta reported positive Phase 2b results for STA-4783 in combination with paclitaxel in a double-blind, randomized, controlled, multi-center clinical trial in patients with stage IV metastatic melanoma. In November 2006, Synta received Fast Track designation from the FDA for the development of STA-4783 in metastatic melanoma. Synta plans to initiate a pivotal Phase 3 clinical trial for STA-4783 in mid-2007 and one or more Phase 2 studies in other cancer indications later in the year.

The schedule and meeting places for the presentation, together with the abstract numbers, are listed below:

Poster Presentations

Tuesday, June 5, 2007 at 8:00 a.m. to 12:00 p.m. - Poster Presentation: 17

Abstract No. 8528

"Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase 2 study of STA-47
'"/>




Page: 1 2 3

Related medicine technology :

1. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
2. Synta Pharmaceuticals to Host Conference Call Today
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
6. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
7. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
8. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
9. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
10. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
11. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
Post Your Comments:
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
(Date:12/22/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ), a global ... epilepsy, today announced it will participate in the 33 rd ... 2015, in San Francisco . ... will speak at 11:00 AM Pacific Time.  A live audio ... the Investor Relations link on the Cyberonics home page at ...
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... 2011   Radiotherapy Clinics of Georgia has announced the ... physicians of Radiotherapy Clinics of Georgia in January.  These courses ... and treatment options. All Prostate Cancer Lecture Series ... a light dinner at 5 p.m. followed by a lecture ...
... Md., Dec. 16, 2011 The U.S. Food and Drug ... heart of children with heart failure to help keep them ... found. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... Pediatric System, made by a German company, Berlin Heart. The ...
Cached Medicine Technology:Radiotherapy Clinics of Georgia Present Prostate Cancer Lecture Series 2FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure 2FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure 3
(Date:12/24/2014)... 24, 2014 The Healthy Home Company has ... raise families. In-Vest USA is dedicated to ... – our first responders. Today, these two organizations have joined ... providing them with body armor through In-Vest’s USA’s Bless the ... that happened this past week in New York. ...
(Date:12/24/2014)... There’s a lot going on with The Affordable Care ... control of the Senate as well as the House, a ... lawsuit has been brought against President Obama by the House, ... have resulted in changes to the law without the approval ... place to weigh the validity of subsidies provided to low ...
(Date:12/24/2014)... “ Relax Melodies ” was featured on NewsWatch ... latest and coolest mobile applications on the iOS, Android, ... and host of NewsWatch, conducted the app review and ... they can fall asleep. , According to the National ... some sort of difficulty sleeping. Since that’s a huge ...
(Date:12/24/2014)... 2014 Dr. Ronald Receveur, a ... placing dental implants in a day, has ... of overusing teeth-whitening treatments. , In his blog ... Dr. Receveur writes that overusing teeth-whitening treatments can lead ... to enamel. , “Because teeth-whitening treatments are ...
(Date:12/24/2014)... year, more than one-third of the more than 10,000 ... extreme heat conditions, according to recent federal statistics. ... the leading cause of heat-related illness among Americans, but ... infections, also put older people at higher risk for ... help health care systems anticipate and perhaps prevent many ...
Breaking Medicine News(10 mins):Health News:The Healthy Home Company and In-Vest USA Team Up to Save the Lives of Law Enforcement 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3Health News:An Application to Help with Insomnia was Featured on NewsWatch Television on December 19, 2014 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 3Health News:Heat Stroke, Kidney Failure Help Drive Illnesses From Extreme Heat 2
... Key New Products Including Completing CE Mark, ... -, TSX Venture Exchange: NVC,VANCOUVER, April ... that it has completed a previously announced non-brokered private ... of $0.21 per unit for aggregate gross proceeds of ...
... Copenhagen, Denmark, Friday 24 April: HIV positive and ... transplant, according to new research presented today at EASL ... the Study of Liver in Copenhagen, Denmark. , The ... 1 and 5 years between HIV negative and HIV ...
... highest standards in the security industry , ... Freeport, ... Inc. is pleased to announce it has once again been awarded ... Alarm Association (CSAA)., , , , ,There are approximately 2,700 central ...
... community and helps individuals with vision care and restoration. , ... ... Christian is an affluent, prestigious, private high school, nestled in the ... their efforts and dedication toward educating America,s youth, by donating several ...
... much as younger ones, , , THURSDAY, April 23 (HealthDay ... older than 50 -- even if they,ve had several ... level of risk as younger women, European researchers contend. ... repeating smear tests in women 60 to 65 years ...
... MINNEAPOLIS, April 23 As federal policymakers pursue healthcare ... health promotion and disease prevention will be critically evaluated. ... more than 40 of North America,s top medical schools ... original scientific research in the area of integrative medicine. ...
Cached Medicine News:Health News:Neovasc Completes $2 Million Non-Brokered Private Placement 2Health News:Neovasc Completes $2 Million Non-Brokered Private Placement 3Health News:HIV positive and HIV negative patients have similar survival rates following liver transplant 2Health News:New York Merchants Protective Co. Renews CSAA Five Diamond Certification 2Health News:New York Merchants Protective Co. Renews CSAA Five Diamond Certification 3Health News:Khanna Institute Supports Oaks Christian School's Annual Fundraiser 2Health News:Don't Lower Age for Cervical Cancer Test, Study Urges 2Health News:Advancements in Integrative Medicine Research to Be Evaluated by Scientists From Leading International Academic Health Centers 2
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
The CGVL vitrectomy contact glass was designed by Rol, Fankhauser et al. for photodisruptive YAG laser procedures in the posterior vitreous....
For newly born children 10 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
... uses a classical distance-independent measuring principle which ... The size of the mire image is ... and the measured object; 2. The resulting ... the Ophthalmometer and the measured object; 3. ...
Medicine Products: